Erius syrup 0.5 mg/ml. 60 ml. vial №1


Manufacturer: Belgium

To eliminate symptoms associated with allergic rhinitis, such as sneezing, nasal discharge, itching, swelling and nasal congestion, as well as itchy and red eyes, watery eyes, itchy palate, and cough. To eliminate symptoms associated with urticaria, such as itching and rashes.



Erius Composition
active substance: desloratadine 1 ml of syrup contains 0.5 mg of desloratadine.

excipients: propylene glycol, sorbitol solution that does not crystallize, citric acid, sodium citrate dihydrate, sodium benzoate (E 211), Trilon B, sucrose, natural and artificial flavoring with chewing gum flavor (No. 15864), yellow colorant FD & C No. 6 (E 110), purified water.

Erius Dosage form

Basic physical and chemical properties: transparent orange liquid.

Pharmacotherapeutic group
Antihistamines for systemic use. ATX code R06A X27.

Desloratadine is a potent selective peripheral H1 receptor blocker that does not have a sedative effect. Desloratadine is the primary active metabolite of loratadine.

After administration, Erius selectively blocks peripheral H1-histamine receptors, since the drug almost does not penetrate the blood-brain barrier.

Numerous studies have shown that in addition to antihistamine activity, Erius has demonstrated its anti-allergic and anti-inflammatory properties. It was found that Erius suppresses a cascade of various reactions underlying allergic inflammation, namely:

release of pro-inflammatory cytokines, including IL-4, IL-6, IL-8, IL-13;
the release of pro-inflammatory chemokines such as RANTES;
superoxide anion production by activated polymorphonuclear neutrophils;
eosinophil adhesion and chemotaxis;
the expression of adhesion molecules such as P-selectin;
IgE-dependent release of histamine, prostaglandin D2 and leukotriene C4;
acute allergic bronchospasm and allergic cough in animal studies.
The safety of using Erius in children has been demonstrated in 3 clinical studies. The drug was prescribed for children from 6 months to 11 years old, who needed antihistamine therapy, in a daily dose of 1 mg (age group from 6 to 11 months), 1.25 mg (age group from 1 to 5 years) or 2.5 mg (age group from 6 to 11 years old). The treatment was well tolerated, which was confirmed by the results of clinical laboratory studies, the state of vital functions of the body and ECG data (including the length of the QT interval).

Erius Pharmacokinetics
Desloratadine begins to be detected in plasma within 30 minutes after taking the drug. Erius effectively controls symptoms for 24 hours. Desloratadine is well absorbed. The maximum concentration of desloratadine in plasma is reached on average after 3:00, the half-life is on average 27 hours. The degree of cumulation of desloratadine corresponds to its half-life (approximately 27 hours) and the frequency of use (once a day). The bioavailability of desloratadine was dose proportional, ranging from 5 to 20 mg.

Desloratadine moderately (83-87%) binds to plasma proteins. When using desloratadine at a dose of 5 to 20 mg once a day for 14 days, there were no signs of clinically significant cumulation of the drug.

A low metabolic rate of desloratadine was noted in about 8% of subjects, in which there was a significant increase in plasma levels of the drug and a lengthening half-life. The prevalence of metabolic slowdowns may be due to race. This fact is still considered clinically irrelevant.

For the relief of symptoms associated with allergic rhinitis, such as sneezing, nasal discharge, itching, swelling and nasal congestion, as well as itchy and red eyes, watery eyes, itchy palate and coughing.

For the relief of symptoms associated with hives, such as itching and rashes.

Hypersensitivity to desloratadine, to any auxiliary component of the drug, or to loratadine.